MetaCap

Lycia Therapeutics Inc. (LYCA)

NASDAQ: LYCAHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD

33.07+1.30 (+4.09%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

LYCA stock chart

Technical analysis

Key statistics

All statistics
EPS (TTM)
-$1.04
52-week range
22.19 – 36.49
Day range
31.01 – 34.59
Volume / Avg
422.14K / 432.72K
Beta
—

52-week range

$22.19$36.49

LYCA stock today

Shares of Lycia Therapeutics (LYCA) finished higher on Nov 20 at $33.07, a gain of 4.09% or $1.30 per share, versus the S&P 500's 3.70% decline. Shares are 9.4% below their 52-week high of $36.49, set on Oct 23, 2026 and 49.0% above the 52-week low of $22.19, in the middle of the past year's range. Lycia Therapeutics has posted a net loss over the last twelve months (EPS of -$1.04), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Lycia Therapeutics

Company profile

Lycia Therapeutics, Inc., a biotechnology company, engages in the discovery and development of therapeutics designed to degrade disease-causing extracellular proteins for the treatment of autoimmune, inflammatory, and allergic diseases. The company develops the LYTAC platform, a modular technology designed to create therapeutics that selectively reduce the levels of pathogenic proteins. Its therapeutic candidate LCA-0061 degrades immunoglobulin E (IgE) for the treatment of allergic diseases, including food allergy.

Industry
Biotechnology: Biological Products (No Diagnostic Substances)
CEO
Dr. Aetna Wun Trombley Ph.D.
Headquarters
South San Francisco, CA
Employees
31
IPO year
2026

LYCA news

All LYCA news

Lycia Therapeutics peers

Health Care sector
LYCA peer companies
CompanyPrice% ChgMarket capCompare
MAZEMaze Therapeutics Inc.31.37-3.27%$1.72Bvs LYCA
REPLReplimune Group Inc.19.07-0.83%$1.81Bvs LYCA
COAGHemab Therapeutics Holdings Inc.39.29-1.43%$1.84Bvs LYCA
BCRXBioCryst Pharmaceuticals Inc.7.22-1.37%$1.86Bvs LYCA
VIRVir Biotechnology Inc.8.39-5.41%$1.56Bvs LYCA
RXRXRecursion Pharmaceuticals Inc. Class A2.45-9.93%$1.53Bvs LYCA
ALVOAlvotech4.12-3.96%$1.47Bvs LYCA
WWBWindward Bio Group AG24.29+1.15%$1.45Bvs LYCA

Indexes, lists and sector

Lycia Therapeutics stock FAQ

What is Lycia Therapeutics's stock price today?

LYCA last traded at $33.07 as of Nov 20, 4:00 PM EST, up 4.09% on the day. Prices are delayed at least 15 minutes.

Who is Lycia Therapeutics's CEO?

Dr. Aetna Wun Trombley Ph.D. is the chief executive officer of Lycia Therapeutics Inc., which has about 31 employees.

What is the LYCA 52-week high?

The 52-week high for LYCA is $36.49 and the 52-week low is $22.19. The stock is currently 9.4% below its high.

Compare LYCA